Nicolas Bertrand
Overview
Explore the profile of Nicolas Bertrand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
3212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ningarhari M, Bertez M, Ploquin A, Bertrand N, Desauw C, Cattan S, et al.
Liver Int
. 2023 Nov;
44(3):682-690.
PMID: 38031969
Background & Aims: Progresses in management make a higher proportion of cirrhotic patients with gastrointestinal (GI) cancer candidates to chemotherapy. Data are needed on the safety and liver-related events associated...
12.
Galvin A, Bertrand N, Boulahssass R, de Decker L, Dorval E, Clairaz B, et al.
J Geriatr Oncol
. 2023 Sep;
15(1):101608.
PMID: 37684193
No abstract available.
13.
Herledan C, Toulemonde A, Clairet A, Boulin M, Falandry C, de Decker L, et al.
Crit Rev Oncol Hematol
. 2023 Sep;
190:104117.
PMID: 37660933
Optimizing anticancer treatment and medication therapy in older patients with cancer requires a multidisciplinary approach, with a strong collaboration between geriatricians, oncologists and pharmacists. While all patients can benefit, some...
14.
Gazaille C, Bozzato E, Madadian-Bozorg N, Mellinger A, Sicot M, Farooq U, et al.
Biomater Adv
. 2023 Jul;
153:213549.
PMID: 37453243
The objective of this work was to develop an implantable therapeutic hydrogel that will ensure continuity in treatment between surgery and radiochemotherapy for patients with glioblastoma (GBM). A hydrogel of...
15.
Madadian Bozorg N, Leclercq M, Lescot T, Bazin M, Gaudreault N, Dikpati A, et al.
Biomater Adv
. 2023 Jul;
153:213533.
PMID: 37392520
In the biomedical field, 3D printing has the potential to deliver on some of the promises of personalized therapy, notably by enabling point-of-care fabrication of medical devices, dosage forms and...
16.
Porlier A, Gagnon P, Chenard V, Veillette M, Bertrand N, Duchaine C, et al.
J Pharm Sci
. 2023 Jun;
112(9):2412-2418.
PMID: 37390868
Durvalumab is a monoclonal antibody approved for the treatment of lung, urothelial and biliary tract cancers. Durvalumab is supplied in vials as a solution containing no preservatives. Monographs recommend single...
17.
Mohammadi F, Dikpati A, Bertrand N, Rudkowska I
Nutr Rev
. 2023 May;
82(2):262-276.
PMID: 37221703
Studies have reported the potential benefits of consuming conjugated linoleic acid (CLA) and ruminant trans fatty acids (R-TFAs) in reducing the risk factors of metabolic syndrome (MetS). In addition, encapsulation...
18.
Roussel S, Grenier P, Chenard V, Bertrand N
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986630
Fluorescent labelling is commonly used to monitor the biodistribution of nanomedicines. However, meaningful interpretation of the results requires that the fluorescent label remains attached to the nanomedicine. In this work,...
19.
Mohammadi F, Green M, Tolsdorf E, Greffard K, Leclercq M, Bilodeau J, et al.
Nutrients
. 2023 Mar;
15(6).
PMID: 36986163
Industrially originated trans-fatty acids (I-FAs), such as elaidic acid (EA), and ruminant trans-fatty acids (R-FAs), such as -palmitoleic acid (TPA), may have opposite effects on metabolic health. The objective was...
20.
Bertrand N, Bridoux M, Gaxatte C, Abi Rached H, Turpin A, Letarouilly J, et al.
Joint Bone Spine
. 2023 Feb;
90(4):105549.
PMID: 36796583
The occurrence of bone fractures is frequent in the elderly population, and in cancer patients, especially with bone metastases. The growing incidence of cancer associated with an aging population implies...